Non-alcoholic fatty liver disease (NAFLD) is a prevalent and progressive liver disease, affecting approximately 25% of the global population. This article provides a comprehensive overview of NAFLD, its pathophysiology, diagnosis, and management.
NAFLD is characterized by the accumulation of excess fat in the liver, unrelated to alcohol consumption. It is closely associated with metabolic syndrome, obesity, insulin resistance, and type 2 diabetes. The disease spectrum ranges from simple steatosis to non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis and hepatocellular carcinoma.
NAFLD is often asymptomatic and may be incidentally diagnosed during routine blood tests or imaging studies. Liver biopsy remains the gold standard for diagnosing NASH and assessing fibrosis. However, non-invasive tests like elastography and serum biomarkers are increasingly used due to their safety and convenience.
The primary management strategy for NAFLD involves lifestyle modifications, including weight loss, healthy diet, and regular exercise. Pharmacological interventions are considered for patients with NASH or significant fibrosis. Currently, Vitamin E and Pioglitazone have shown some benefits in these patients. Several new drugs targeting different pathophysiological pathways are under investigation.
Healthcare professionals play a crucial role in the early detection and management of NAFLD. They should educate patients about the importance of lifestyle changes and monitor them regularly for disease progression. Multidisciplinary approach involving hepatologists, dietitians, and endocrinologists may be beneficial in managing this complex disease.
NAFLD is a significant global health issue with potential serious outcomes. Understanding its pathophysiology, diagnosis, and management strategies is essential for healthcare professionals to effectively manage this disease and prevent its progression.
1.
Research uncovers hidden Australian skin cancer epidemic
2.
What Could This Exploratory 5-Year Survival Data in Adjuvant NSCLC Treatment Mean?
3.
The clinical trial of ENZAMET shows promise as a treatment for prostate cancer.
4.
Cancer Vaccines' Emergence; More Focus on Side Effects; A Nudge for Exercise.
5.
Using MRD Status to Deescalate Multiple Myeloma Therapy
1.
Understanding Purpura Fulminans: Causes, Symptoms and Treatment Options
2.
The Importance of Maintaining Normal Calcium Levels in Your Body
3.
The Checkpoint Architect: Unraveling the Mechanisms of PD-L1 Regulation for the Next Generation of Small-Molecule Therapies
4.
Metabolic Symbiosis Within the Tumor Niche: Mechanisms, Clinical Implications, and Therapeutic Opportunities
5.
A Comprehensive Guide to Carcinoma in Situ: Types, Risks, and Preventive Measures
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
2.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
3.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
4.
Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.
5.
Latest Advances in Hematology
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation